Skip to main content
Clinical Trials/NL-OMON44348
NL-OMON44348
Completed
N/A

Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate - GABA and glutamate in cognitive impairment in MS

Anatomie en Neurowetenschappen0 sites75 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Anatomie en Neurowetenschappen
Enrollment
75
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Anatomie en Neurowetenschappen

Eligibility Criteria

Inclusion Criteria

  • To participate in the MRI part of the study:
  • \- Clinically definite Relapsing Remitting or Secondary Progressive Multiple sclerosis
  • \- Sufficient visual acuity and motor performance to perform the MRI task
  • \- Between 18 and 60 years of age;To participate in the PET\-part of the study:
  • \- Minimum hemoglobin values of 8 g/dl for men and 7 g/dl for women

Exclusion Criteria

  • For the MRI\-part of the study:
  • \- MR contraindications
  • \- Neurological and/or psychiatric disorders (other than MS; e.g. depression, schizophrenia, alcohol or drug abuse)
  • \- For MS patients: the use of corticosteroids in the 4 weeks prior to inclusion. ;For the PET\-part of the study:
  • \- benzodiazepine use or other drug use that affects the benzodiazepine site on the GABA receptor system (e.g. imidazopyridines, pyrazolopryimidines en cyclopyrrolones) 6 weeks or less before the start of the study.
  • \- The use of GHB (gamma\-hydroxybutyrate)
  • \- In the case of pregnancy or breastfeeding
  • \- Insufficient haemoglobin value values as discussed in the inclusion criteria.
  • \- (a history of) significant cardiac disease
  • \- exposure to previous radiation leading to an annual cumulative dose of more than 10mSv

Outcomes

Primary Outcomes

Not specified

Similar Trials